Skip to main content

Table 4 Observed Incidence of Febrile Neutropenia

From: Efficacy and safety of RGB-02, a pegfilgrastim biosimilar to prevent chemotherapy-induced neutropenia: results of a randomized, double-blind phase III clinical study vs. reference pegfilgrastim in patients with breast cancer receiving chemotherapy

 

RGB-02

Reference

Difference(RGB-02 - Reference)

Cycle 1, PP population

 n

117

113

 

 n (%) with febrile neutropenia

5 (4.3)

4 (3.5)

 

 Proportion (95% CI) with febrile neutropenia

0.043 (0.014, 0.097)

0.035(0.010, 0.088)

0.007(−0.123, 0.137)

Cycle 2, PP population

 n

111

103

 

 n (%) with febrile neutropenia

0

0